title: Side effects of systemic oncological therapies in dermatology.
abstract: The discovery of specific gene mutations, termed "driver mutations", in different tumors has brought personalized medicine into the focus of cancer treatment. Targeted treatment agents generally are administered orally and have a tolerable adverse event profile; they have become widely used in both inpatient and outpatient settings. The approval of the selective BRAF inhibitor vemurafenib (Zelboraf®) as first-line therapy of metastatic melanoma in Europe in February 2012 as well as the increasing use of MEK inhibitors within clinical trials confronts dermatologists and oncologists with a new spectrum of side effects. Knowledge of these possible adverse events and their management will be crucial for optimized patient care. This article offers an overview of the most important adverse events of currently employed dermato-oncologic therapeutic agents.
authors.affiliation: Department of Dermatology, Skin Tumor Center, University Hospital of Essen, Germany.
authors.forename: Lisa
authors.initials: L
authors.lastname: Zimmer
authors.forename: Julia
authors.initials: J
authors.lastname: Vaubel
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Livingstone
authors.forename: Dirk
authors.initials: D
authors.lastname: Schadendorf
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans
chemical_list: D000970:Antineoplastic Agents